FDA demands new trial for Lilly's Arxxant

The FDA is demanding that Eli Lilly undertake a new three-year, late-stage trial to demonstrate the efficacy of its diabetic eye disease therapy, dubbed Arxxant. Lilly had received an approvable letter in August and had hoped that the FDA's concerns could be satisfied from the existing data. Now the drug developer says they're going to continue ongoing studies while pondering the agency's demand for a new pivotal trial of ruboxistaurin, which Lilly says would actually take five years to complete.

- read the AFX report on Lilly's dilemma

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.